Nu Skin Enterprises, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NUS research report →
Range $11 – $11
Price Chart
About the company
Nu Skin Enterprises, Inc. (NUS) is a global enterprise dedicated to the creation and worldwide distribution of beauty and wellness solutions. The company's diverse product offerings encompass advanced skincare systems, such as the ageLOC Spa and ageLOC Transformation age-defying lines, innovative devices like the ageLOC LumiSpa for comprehensive skin treatment and cleansing, and the ageLOC Boost, alongside various other cosmetic and personal care items.
- CEO
- Ryan S. Napierski
- IPO
- 1996
- Employees
- 2,800
- HQ
- Provo, UT, US
Get TickerSpark's AI analysis on NUS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $184.98M
- P/E
- -0.78
- Fwd P/E
- 6.33
- PEG
- 0.00
- P/S
- 0.14
- P/B
- 0.34
- EV/EBITDA
- 8.66
- Div Yield
- 6.37%
- Gross Margin
- 67.84%
- Op Margin
- -1.90%
- Net Margin
- -17.72%
- ROE
- -34.83%
- ROIC
- -2.88%
Latest fiscal year · YoY change
- Revenue
- $1.49B-14.3%
- Gross Profit
- $1.03B-12.7%
- Op Income
- $90.88M
- Net Income
- $160.20M+209.3%
- EPS
- $3.25+210.2%
- OCF Growth
- -28.2%
- FCF Growth
- -34.4%
- 52W High
- $11.67
- 52W Low
- $3.75
- 50D MA
- $4.60
- 200D MA
- $5.93
- Beta
- 0.93
- RSI (14)
- 34
- Avg Volume
- 525.74K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Nu Skin posted a modest Q3 beat versus guidance, but the core business remained pressured even as Prysm, cost actions, and the East-West restructuring support a more profitable long-term setup.· November 5, 2026
- Q3 revenue was $311 million and adjusted EPS was $0.10, both within guidance.
- Gross margin fell to 65% from 70.5% a year ago, mainly due to mix between core Nu Skin and Rhyz.
- Prysm momentum improved: 41,000 devices placed, 4.5 million scans completed, and scan-to-purchase conversion more than doubled to 10% after the app update.
- Management is investing in sales force training and a more programmatic incentive structure, while saying short-term promotions are less effective.
- Full-year guidance was reaffirmed/lowered to reflect charges and transition costs, but management expects sequential revenue growth in Q4.
Third-quarter revenue was $311 million, including a 1.1% or $3.9 million foreign currency headwind. Reported EPS was negative $0.02, or $0.10 adjusted after excluding organizational transition costs and certain other charges. Gross margin was 65% versus 70.5% in the prior year; core Nu Skin gross margin was 76.6% versus 77.7%. Selling expense was 33.2% of revenue versus 35.8% a year ago, and adjusted operating margin was 3.7% versus 5.9%. For Q4, the company expects revenue of $310 million-$340 million, reported EPS of $0.05-$0.15, and adjusted EPS of $0.11-$0.21. For full-year 2026, it expects revenue of $1.26 billion-$1.29 billion, reported EPS of negative $5.08 to negative $4.98, and adjusted EPS of $0.55-$0.65. The full-year outlook includes an anticipated 1% foreign currency headwind and about $5 million of remaining cash-based organizational transition costs in Q4, with an effective tax rate of approximately 39% after adjustments.
Ryan Napierski framed the quarter around long-term restructuring and platform-building rather than near-term top-line growth. He highlighted four priorities: advancing the integrated anti-aging platform, strengthening the sales channel, preparing for India’s formal launch in the first half of 2027, and improving the operating model for better profitability. His tone was constructive but candid, acknowledging ongoing pressure in the core business while emphasizing that the new East-West structure, Prysm engagement, and leadership development should improve efficiency and sustainable growth over time.
Chelsea Lantz focused on the mechanics of the quarter and the path to profitability. She cited $311 million of revenue, 65% gross margin, 33.2% selling expense, 30.2% G&A as a percentage of revenue, and 3.7% adjusted operating margin, all against tougher year-over-year comparisons and mix pressure. She also noted $164.9 million of cash and cash equivalents, total debt of $203.7 million, $2.9 million returned via dividends, no share repurchases, and $137.3 million remaining under the buyback authorization. On the outlook, she pointed to about $5 million of remaining Q4 transition costs excluded from adjusted EPS and reiterated that the company is right-sizing its cost base while preserving strategic investment.
The main analyst focus was how Nu Skin plans to rebuild channel momentum and whether more incentives were coming. Ryan said the company is relying less on short-term promotions and more on a sustained programmatic approach, including compensation plan enhancements, an incentive roadmap aligned for 2027, and leadership training that better fits modern social-media-driven selling. On Prysm, he said the 10% scan-to-purchase conversion is still early and that there is room for improvement as the app’s AI-driven recommendations improve engagement; he also stressed that the device supports both acquisition and retention rather than being a pure conversion tool.
The bull case is that Nu Skin is seeing early evidence that its strategic investments can improve engagement: Prysm scans, conversion, and LifePak demand are moving in the right direction. Management also sees the East-West operating model and manufacturing closer to customers as levers for better gross margin, speed to market, and fixed-cost efficiency over time.
The bear case is that the core business is still under pressure, with revenue and margins below prior-year levels and management explicitly saying customer and sales metrics remain weak. Full-year reported EPS is heavily affected by non-cash charges and the business still needs to execute on restructuring, channel rebuilding, and the future India launch before growth can reaccelerate.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.1%
- Shares Outstanding
- 48.68M
- Float Shares
- 47.24M
of shares held by institutions
171 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 4.34M | ▲ 123.42K |
| Blackrock, Inc. | 4.22M | ▼ 99.43K |
| American Century Companies Inc | 2.69M | ▲ 390.63K |
| Vanguard Capital Management LLC | 2.09M | ▲ 41.07K |
| Castleknight Management LP | 1.97M | ▲ 583.54K |
| Acadian Asset Management LLC | 1.95M | ▼ 4.95K |
| Vanguard Portfolio Management LLC | 1.77M | ▲ 36.23K |
| Prescott Group Capital Management, L.L.C. | 1.60M | ▼ 191.33K |
| Renaissance Technologies LLC | 1.54M | ▼ 72.40K |
| Dimensional Fund Advisors LP | 1.34M | ▼ 455.81K |
| Goldman Sachs Group Inc | 1.16M | ▲ 541.18K |
| Geode Capital Management, LLC | 1.10M | ▼ 171.77K |
Held by 173 ETFs
Biggest fund positions in NUS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 9, 26 | WOODBURY EDWINA D | other | 22 |
| Jun 10, 26 | WOODBURY EDWINA D | other | 19 |
| May 11, 26 | Nathanson Laura | sell | 2,676 |
| Mar 18, 26 | Lantz Chelsea K | other | 0 |
| Mar 11, 26 | WOODBURY EDWINA D | other | 14 |
| Mar 6, 26 | Keisel Justin S | other | 47,059 |
| Mar 6, 26 | Hatchett Steven Keith | other | 77,941 |
| Mar 6, 26 | Clark Chayce David | other | 138,971 |
| Mar 6, 26 | Thomas James D | other | 114,706 |
| Mar 6, 26 | NAPIERSKI RYAN S | other | 282,353 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NUS coverage
Recent articles, reports, and earnings notes.
No research on NUS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NUS report →What Nu Skin Enterprises (NUS) Said on Its Q3 Earnings Call
marketbeat.com · Nov 8
Nu Skin Enterprises, Inc. (NUS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
CORRECTING and REPLACING Nu Skin Enterprises Reports Third Quarter Earnings
businesswire.com · Nov 5
Nu Skin Enterprises Reports Third Quarter Earnings
businesswire.com · Nov 5
Nu Skin Enterprises Announces Quarterly Dividend
businesswire.com · Nov 5
Nu Skin Enterprises to Announce Third Quarter 2026 Financial Results
businesswire.com · Oct 22
Nu Skin Ranked the World's #1 Company for Beauty and Wellness Device Systems for Third Consecutive Year
gurufocus.com · Sep 3
Nu Skin Ranked the World's #1 Company for Beauty and Wellness Device Systems for Third Consecutive Year
businesswire.com · Sep 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.